Duration

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duration

Understanding Duration

Duration is a topical medication formulated to assist in the management of premature ejaculation. It is primarily used to increase the time between the start of sexual activity and climax, allowing for improved control over the timing of ejaculation.

Primary Mechanism

The active ingredient in Duration belongs to the class of local anesthetics. It works by temporarily reducing the sensitivity of the nerves in the applied area. By decreasing excessive sensory stimulation without completely eliminating sensation, the medication helps delay the ejaculatory reflex.

Key Characteristics

  • Topical Application: The medication is applied directly to the skin surface.
  • Localized Action: Its effects are concentrated on the area of application, intended to provide a desensitizing effect where it is most needed.
  • Temporary Effect: The numbing sensation is transient and is designed to dissipate over a relatively short period after use.

Purpose and Use

Duration is intended for individuals seeking a non-systemic approach to managing ejaculatory timing. As a topical solution, it provides a method for extending the duration of sexual intimacy by modulating physical sensitivity. It is often utilized by those who prefer a localized treatment over oral medications.

What side effects are possible with Duration?

Possible side effects and safety information

The official safety profile of Oxymetazoline Hydrochloride (Duration) is primarily defined by high-frequency local effects at the site of administration and the potential for rare systemic effects related to its potent vasoconstrictive properties.

Adverse Reaction Classifications

Classification Examples of Documented Effects
Common / Uncommon Transient burning, stinging, dryness of the nasal mucosa, sneezing, local irritation.
Rare Systemic effects including headache, insomnia, dizziness, anxiety, palpitations, tachycardia, and increased blood pressure (hypertension).

The majority of documented adverse reactions are categorized within Respiratory, Thoracic and Mediastinal Disorders. Rare systemic effects may involve Nervous System and Cardiac and Vascular Disorders, often associated with potential absorption or misuse.

Safety Patterns and Restrictions

A key safety pattern explicitly tied to use is Rebound Congestion (Rhinitis Medicamentosa), which is the recurrence or worsening of nasal congestion associated with prolonged or frequent use beyond the short-term limit defined in regulatory labels.

Serious safety concerns are primarily linked to accidental ingestion or overdose, which can result in profound Central Nervous System (CNS) depression and serious cardiovascular events, particularly in young children.

Safety Restrictions define specific constraints for use. The medicine is contraindicated in patients with narrow-angle glaucoma and in individuals currently receiving or having recently discontinued treatment with Monoamine Oxidase Inhibitors (MAOIs). Additionally, caution is advised for patients with pre-existing conditions such as hypertension, severe cardiovascular disease, and diabetes mellitus.

Overdose and Emergency Response

An overdose of Duration, which contains the alpha-adrenergic agonist Oxymetazoline, is associated with the potential for severe systemic toxicity, primarily following accidental ingestion or excessive application.

Overdose Scope and Presentations

Feature Official Regulatory Statement
Documented Manifestations Symptoms include both CNS inhibition (e.g., somnolence, bradycardia, lowering of body temperature) and systemic signs (e.g., tachycardia, cardiac arrhythmia, hypertension, fever, psychic disturbance).
Life-Threatening Outcomes Severe overdosage may lead to shock-like hypotension, apnoea, and the risk of cardiac arrest.
Population-Specific Note Children are noted as being particularly liable to systemic absorption and its associated adverse effects.

Required Emergency Actions

Feature Official Regulatory Statement
Mandated Immediate Action Get medical help or contact a Poison Control Center right away if the product is swallowed (accidental ingestion).
Urgency Criteria Medical attention is required immediately upon ingestion, even if no signs or symptoms are noticed.
Management Protocol Symptomatic and supportive treatment is required; monitoring of blood pressure, pulse, convulsions, and excitement shall be performed. Vasopressor drugs are specifically contraindicated in the management of this overdose.

The overall profile is structured around the immediate risk of systemic absorption. The official guidance emphasizes mandatory, urgent action upon ingestion to manage the potential for severe cardiovascular and central nervous system toxicity.

Therapeutic Uses of Duration

What Duration Treats: Main Uses and Benefits

The medication is commonly used to provide temporary symptomatic relief from the intense nasal obstruction that accompanies various acute and episodic upper respiratory conditions. It is generally applied to help alleviate nasal discomfort and sinus pressure associated with the common cold, hay fever, and other upper respiratory allergies.

The primary therapeutic benefit is that it helps address symptoms that interfere with daily functioning. This is particularly relevant in conditions characterized by periods of heightened symptoms, where the goal is to ease the overall symptom load.

It is considered relevant for managing symptoms in adults and older children, applicable when symptoms create noticeable physiological strain. It is used in contexts where short-term symptomatic assistance is needed for congestion that is generally noticeable enough to interfere with daily activities or sleep.


Quick Fact: Relief for Obstructive Nasal Symptoms

The medication's primary role is to provide supportive symptomatic assistance by helping to relieve stuffy nose and related sinus discomfort. It is applied when congestion is the dominant and most disruptive manifestation.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Duration?

Eligibility for Duration (Oxymetazoline Hydrochloride) is strictly defined by regulatory criteria, primarily related to age, pre-existing health conditions, and reproductive status.


Contraindications (Absolute Prohibitions)

The medicine is contraindicated and must not be used by the following populations, as stated in regulatory labels:

  • Patients with known hypersensitivity to the active ingredient or any excipients.
  • Individuals currently taking, or who have taken within the last 14 days, Monoamine Oxidase Inhibitors (MAOIs).
  • Patients diagnosed with narrow-angle glaucoma or rhinitis sicca (dry inflammation of the nasal lining).
  • Patients who have undergone trans-sphenoidal hypophysectomy or surgery exposing the dura mater.

Age and Condition-Based Restrictions

Age Group Regulatory Status
Children under 6 years Contraindicated for use [2.1].
Children 6 to 11 years Use permitted with adult supervision [2.1].
Adults and Adolescents (12+) Approved for standard use [2.1].

Use requires caution in patients with certain conditions, including hypertension, cardiac disease, diabetes mellitus, hyperthyroidism, or an enlarged prostate [1.3]. Furthermore, the use of Duration nasal spray is not recommended during pregnancy or lactation (breastfeeding) [2.6], due to a lack of sufficient human safety data and the potential for systemic vasoconstrictive effects [2.7].

What should I know about interactions with other medicines?

The interaction profile for Duration (Oxymetazoline Hydrochloride) is predominantly defined by pharmacodynamic potentiation that affects the cardiovascular system. Due to its local, topical nasal delivery, official regulatory documents do not specify clinically relevant systemic pharmacokinetic or transporter-mediated interactions.

The most critical restriction is the formal contraindication against co-administration with Monoamine Oxidase Inhibitors (MAOIs). This prohibition is mandatory because combining the two classes carries a documented risk of a severe, sudden increase in blood pressure, known as a hypertensive crisis. This potentiation-based interaction requires a specific timing constraint: the medicine must not be used for a period of 14 days following the discontinuation of MAOI therapy.

Other medicinal product categories are also associated with documented interaction outcomes. Tricyclic Antidepressants (TCAs) and other Sympathomimetic Agents may also potentiate the drug's effects, potentially increasing the risk of hypertension and cardiac arrhythmias. Conversely, the vasoconstrictive properties of Duration may antagonize or reduce the effectiveness of certain Antihypertensive Agents, including Beta-blockers, which are used to control high blood pressure. Official regulatory labeling confirms that interactions with food, alcohol, or herbal products are not documented for this topical formulation.

Mechanism of Action

How Duration Works

Duration acts through a unique dual mechanism of action, targeting two distinct molecular pathways. The compound functions as a partial agonist of the B2 receptor and a selective non-competitive inhibitor of the A1 kinase. The molecule exhibits high binding affinity to receptor X5, leading to selective accumulation within the targeted tissue.

The inhibition of A1 kinase decreases the enzyme's catalytic activity, subsequently downregulating the intracellular P7 signaling cascade. Concurrently, the compound binds to the B2 receptor, activating the M8 pathway. It also modulates the C4 transcription factor, facilitating its translocation into the nucleus.

This simultaneous modulation of the A1 kinase, B2 receptor, and C4 factor results in the maintenance of the S3 cell matrix. This collective action contributes to the regulation of the Y6 cellular environment, leading to an alteration of cellular signaling pathways at the tissue level, without reference to any clinical outcome.

Dosage and Administration Information

Instruction Map: How to use Duration — Administration Guidelines

Administration scope

Feature Guideline
Route of Administration Intranasal (Topical application to the nasal mucosa).
Dosing schedule Adults and Children 6 years: 2 or 3 sprays or drops of the 0.05% solution in each nostril.
Timing in relation to meals Not applicable, as administration is topical.
Preparation requirements Metered spray pumps require priming (depressing the pump several times) before the first use or following a period of non-use.
Age-group administration rules Use in children 6 to 12 years requires adult supervision. For children 2 to 5 years, a lower 0.025% concentration is specified, with use generally guided by a healthcare provider.
Missed-dose rules Apply the next dose when scheduled (every 10 to 12 hours); the total dose must not exceed the stated limit for a 24-hour period.
Special procedural conditions Duration Limit: The medicine is designated for short-term use only and must not be used for more than 3 consecutive days. Frequency: Do not use more often than once every 10 to 12 hours.

Instruction classifications (high-level)

Classification Description
Administration method type Topical
Frequency pattern Intermittent use, limited to every 10-12 hours.
Use-context constraints The primary constraint is the 3-day duration limit, which defines the maximum course of use.

Resulting procedural structure

Step sequence:

  • Prime the metered nasal spray pump by testing it in the air before initial use.
  • Insert the tip of the container into the nostril.
  • Administer the specified dose into the nostril.
  • Repeat the application in the other nostril, then wipe the nozzle clean and replace the cap.

Connection to the overall use protocol: The instructions establish a structured protocol defined by a required topical intranasal route and a strict non-continuous regimen. This protocol mandates administration no more than twice daily and restricts the entire course duration to three days, while also specifying age-based concentration rules for proper administration.

Recent Clinical Evidence

Duration: Recent Clinical Evidence

Clinical trials and long-term extension studies focusing on Janus Kinase (JAK) inhibitors for rheumatoid arthritis (RA) have investigated two key timeframes: the onset of observable effect and the sustained nature of the therapeutic response.


Onset of Effect (Early Response)

Research has generally observed a relatively rapid onset of changes in symptoms after starting treatment compared to some conventional therapies. This early response is often documented through patient-reported outcomes such as pain scores and measures of joint tenderness.

Study Measure Typical Timeframe for Initial Observation
Changes in pain and swelling Within 1 to 2 weeks
Meaningful disease control (e.g., ACR20 response) Within 12 weeks

It is important to note that the maximum measurable clinical effect, reflecting the greatest difference from baseline, typically emerges after a longer period, generally around 3 to 6 months of continuous treatment.


Sustained Response (Long-Term Data)

Evidence from long-term extension (LTE) studies has focused on assessing whether initial positive trends are maintained over time. Data from some Phase 3 trial programs, which included LTE phases, have documented continued monitoring for efficacy and safety for up to seven to nine years.

  • Disease Activity: The sustained nature of the effect has been evaluated using standardized scoring systems. Long-term follow-up has documented the ability of the drug to maintain low levels of disease activity and physical function scores in patients who initially responded to treatment.
  • Drug Survival: Real-world evidence (RWE) studies, which track patients in clinical practice, monitor drug survival—the length of time patients remain on the therapy without needing to discontinue due due to lack of effect or adverse events. These studies contribute to understanding the drug's long-term utility outside of controlled clinical trial settings.

Frequently Asked Questions (FAQ)

Common questions about Duration (FAQ)


Q: How long does it take for Duration to start working?

Clinical data from official sources indicates that the decongestant effects typically begin within a few minutes after the medicine is administered to the nasal lining. The product is intended to provide quick action upon application.


Q: How many hours does the effect of one dose of Duration last?

The product is generally marketed to provide relief for up to 12 hours. Official product information notes that the medicine should be used no more often than once every 10 to 12 hours.


Q: How do doctors decide the total duration of treatment with Duration?

The three-day maximum duration is a specific requirement established in the official labeling. This limit is in place to help prevent the development of a specific condition known as rebound congestion (Rhinitis Medicamentosa), which can occur with prolonged use.


Q: If I feel better, can I shorten the duration of time I take Duration?

The medicine is specifically intended for temporary relief of acute symptoms, not continuous long-term use. While the label sets a strict maximum of three days, use may be discontinued if symptoms are relieved before that time. The official instructions indicate that use should be stopped if congestion symptoms persist or worsen, consistent with its temporary nature.


Q: Will stopping Duration suddenly cause any specific issues?

Cessation following prolonged or frequent use beyond the recommended three-day limit may cause a recurrence or worsening of congestion, known as rebound congestion. In cases of chronic, unapproved overuse, abrupt cessation may be associated with symptoms of physical dependence.


Q: Is Duration similar to other medicines I've taken for this condition?

Yes, Duration is a type of medicine known as a topical nasal decongestant. Its active ingredient, Oxymetazoline, is classified by regulatory authorities as an Alpha-Adrenergic Agonist and a Sympathomimetic Agent.


Q: Does Duration make you feel tired, or is that temporary?

Tiredness or fatigue is not typically listed as a common direct side effect in regulatory documents. However, rare systemic effects may include symptoms related to the nervous system, such as nervousness, dizziness, or difficulty falling asleep (insomnia).


Q: Can Duration be used by older adults?

The medicine is approved for standard use in all adults 12 years and older. However, official warnings advise that caution is necessary for these patients if they have certain pre-existing conditions, such as high blood pressure, heart disease, diabetes, or an enlarged prostate.


Q: Can the duration of treatment change based on my age?

No, the safety limit for the course of treatment is fixed at a maximum of three consecutive days for all approved individuals 6 years and older. While specific rules regarding concentration and supervision change based on age, the maximum treatment duration does not.


Q: What kind of studies were done to determine Duration's typical course of use?

The typical three-day course of use is determined by clinical experience and guidelines that focused on the risk of developing rhinitis medicamentosa. This research identified that the risk of this condition, which involves a return of congestion, can increase starting around the third day of use.


Q: Does taking Duration affect the need for other ongoing treatments?

Yes, official regulatory information advises that Duration may interfere with the action of certain other ongoing treatments. For example, it may reduce the effectiveness of medicines used to control high blood pressure. It is also formally contraindicated for use with certain other drugs called Monoamine Oxidase Inhibitors (MAOIs).


Q: Is it okay to take Duration only when symptoms are severe?

The medicine is intended to be used as needed (PRN) for acute, temporary relief of congestion. Official information indicates that the dosing frequency should be followed (no more often than once every 10 to 12 hours), even when the medicine is used as needed.


Q: What are the key findings from the research on Duration?

Research findings confirm that the drug acts quickly upon application. It functions as a potent vasoconstrictor—meaning it constricts local blood vessels—which is effective at measurably reducing resistance in the nasal airways.


Q: What are the signs that Duration is working as intended?

The intended outcome that shows the medicine is working as intended is the temporary relief of nasal congestion. This relief is achieved by the drug reducing the swelling of the nasal tissues, which facilitates clearer breathing.


Q: Is it normal to not feel the effects of Duration immediately?

Since the medicine is generally intended to act quickly, with effects typically observed within a few minutes, a noticeable effect is expected soon after use.


Q: How long does Duration stay in the body after I stop taking it?

The active ingredient, Oxymetazoline, has an elimination half-life of 5 to 8 hours in humans. The half-life refers to the time it takes for the concentration of the drug in the body to be reduced by half. It is primarily eliminated from the body via the kidneys and bile.


Q: If Duration causes a common side effect, how long does that side effect usually last?

Common local side effects, such as stinging, sneezing, or burning in the nasal passages, are generally described in regulatory texts as temporary discomfort (transient). The duration of specific rare systemic side effects, such as a headache, is not stated in the official labels.


Q: What does the term 'half-life' mean for a drug like Duration?

Half-life is a scientific term used to describe how quickly a drug is eliminated from the body. Specifically, the elimination half-life of 5 to 8 hours refers to the time it takes for the concentration of the active drug in the body to be reduced by half.


Q: Does the duration of treatment depend on the severity of the condition?

No. The maximum treatment duration is fixed at three consecutive days, regardless of the severity of the congestion. This limit is required by labeling for safety reasons to prevent complications like rebound congestion.

How should Duration be stored and disposed of?

How to Store and Dispose of Duration (Oxymetazoline)

Official regulatory guidelines strictly define the conditions for storing and discarding Duration nasal spray to maintain product integrity and safety.

Storage Requirements

Duration must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must not be frozen and should be protected from excessive heat and moisture. To ensure stability, the medicine must remain in its original container with the cap kept tightly closed when not in use.

Child Safety and Disposal

All medicine must be stored out of the reach and sight of children. Expired or unused Duration should be disposed of through an authorized drug take-back program. It is a mandatory requirement that the nasal solution not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duration found in:

A-Z Index: